Biogen Inc. agrees to acquire Apellis Pharmaceuticals for $5.6 billion
LONDON – Biogen Inc. (“Biogen”, Nasdaq: BIIB) has entered into a definitive agreement to acquire public portfolio company Apellis Pharmaceuticals, Inc. (“Apellis”, Nasdaq: APLS). Apellis is a commercial-stage biotech advancing treatments for serious, complement-driven diseases. It has two FDA-approved medicines,…